EGFR and lung adenocarcinoma: For advanced lung adenocarcinoma without active driver mutations, such as epidermal growth factor receptor (EGFR) or echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion mutations, instead of targeted therapy, chemotherapy with a platinum-based reagent is the main treatment option if there is no contraindication [3,4,5].